Mostrar el registro sencillo del ítem
| dc.contributor.author | Esteban-Fernández, Alberto | |
| dc.contributor.author | Calvo-Bernal, Beatriz | |
| dc.contributor.author | López-Vilella, Raquel | |
| dc.contributor.author | de-Lara, Gregorio | |
| dc.contributor.author | Belarte-Tornero, Laia-C | |
| dc.contributor.author | Barrantes-Castillo, Moisés | |
| dc.contributor.author | Gómez-Otero, Inés | |
| dc.contributor.author | Núñez-Villota, Julio | |
| dc.contributor.author | Robles-Gamboa, Carolina | |
| dc.contributor.author | López-Aguilera, José | |
| dc.contributor.author | Torremocha-López, Ana | |
| dc.contributor.author | Melendo-Viu, María | |
| dc.contributor.author | Simón-Ramón, Clara | |
| dc.contributor.author | Fluvia-Burgues, Paula | |
| dc.contributor.author | Pastor-Pérez, Francisco-José | |
| dc.contributor.author | Alonso-Salinas, Gonzalo | |
| dc.contributor.author | García-Pinilla, José-Manuel | |
| dc.contributor.author | Pomares-Varo, Antonia | |
| dc.contributor.author | Gayan-Ordas, Jara | |
| dc.contributor.author | González-Calle, David | |
| dc.contributor.author | Díez-Villanueva, Pablo | |
| dc.contributor.author | Galvan-Ruiz, Mario | |
| dc.contributor.author | Ortiz-Cortes, Carolina | |
| dc.contributor.author | Caravaca-Pérez, Pedro | |
| dc.contributor.author | Goena-Vives, Cristina | |
| dc.contributor.author | Seller, Julia | |
| dc.contributor.author | Jiménez-Blanco, Marta | |
| dc.contributor.author | Codina, Pau | |
| dc.contributor.author | Vietiez, José-María | |
| dc.contributor.author | Jordan-Martínez, Laura | |
| dc.contributor.author | López-Lluva, María-Thiscal | |
| dc.contributor.author | Mena-Sebastia, Elisabet | |
| dc.contributor.author | Pajaro, Pedro | |
| dc.contributor.author | Recio-Mayoral, Alejandro | |
| dc.date.accessioned | 2026-09-17T12:13:37Z | |
| dc.date.available | 2026-09-17T12:13:37Z | |
| dc.date.issued | 2026-05-05 | |
| dc.identifier.issn | 2055-5822 | |
| dc.identifier.uri | https://sms.carm.es/ricsmur/handle/123456789/28106 | |
| dc.description.abstract | AIMS: To evaluate the effectiveness and safety of vericiguat in patients with heart failure and reduced ejection fraction (HFrEF) following recent decompensation in routine clinical practice in Spain. METHODS: VERISEC is a prospective, multicentre registry of 835 consecutive patients initiating vericiguat at 41 centres in Spain. Functional class, biochemical markers, ventricular function, and clinical events were analysed during a 1-year follow-up. RESULTS: Patients (age 71.3 years [SD: 11.2], 78.9% male) received highly optimized baseline therapy: 91.5% SGLT2i, 90.7% beta-blockers, 85.4% RAASi, and 79.8% MRAs. Quadruple therapy remained stable (61.7% baseline to 63.0% at 12 months; P = .526). At 1-year follow-up, significant improvements were observed. NT-proBNP decreased from 3532.0 (IQR: 1689.3-6974.5) to 2291.5 pg/ml (IQR: 1063.0-5076.3; P < .001) and LVEF increased from 30.3% (SD: 7.6) to 35.4% (SD: 11.1; P < .001). NYHA class improved, with class II patients increasing from 55.6% to 62.2% (P < .001). Mean HF decompensations requiring intravenous diuretics decreased from 1.34 (SD: 1.1) in the preceding year to 0.65 (SD: 1.3) during follow-up. Non-HF cardiovascular hospitalizations decreased from 0.98 (SD: 1.4) to 0.39 (SD: 1.0). Vericiguat was discontinued in 13.4% of patients, primarily due to symptomatic hypotension (49.4%). Higher baseline NT-proBNP (per 1000-pg/ml increase) independently predicted discontinuation (OR: 1.06; 95% CI: 1.03-1.08; P < .001). CONCLUSIONS: Vericiguat added to optimized quadruple therapy was associated with reverse remodelling, reduced NT-proBNP, improved functional class, and a numerical reduction in HF-related events in real-world HFrEF patients. These findings confirm the clinical utility and safety of vericiguat in routine practice. | |
| dc.language.iso | eng | |
| dc.publisher | OXFORD UNIV PRESS | |
| dc.rights | Atribución/Reconocimiento 4.0 Internaciona | |
| dc.rights.uri | https://creativecommons.org/licenses/by/4.0/deed.es | * |
| dc.subject.mesh | Aged | |
| dc.subject.mesh | Female | |
| dc.subject.mesh | Humans | |
| dc.subject.mesh | Male | |
| dc.subject.mesh | Follow-Up Studies | |
| dc.subject.mesh | Heart Failure/drug therapy/physiopathology/epidemiology | |
| dc.subject.mesh | Prospective Studies | |
| dc.subject.mesh | Registries | |
| dc.subject.mesh | Spain/epidemiology | |
| dc.subject.mesh | Stroke Volume/physiology/drug effects | |
| dc.subject.mesh | Time Factors | |
| dc.subject.mesh | Treatment Outcome | |
| dc.subject.mesh | Ventricular Function, Left/physiology/drug effects | |
| dc.title | One-year multicenter prospective real-world study of vericiguat effectiveness and safety in Spain | |
| dc.type | info:eu-repo/semantics/article | |
| dc.identifier.pmid | 42128540 | |
| dc.relation.publisherversion | https://academic.oup.com/eschf/article/doi/10.1093/eschf/xvag138/8677720 | |
| dc.type.version | info:eu-repo/semantics/publishedVersion | |
| dc.identifier.doi | 10.1093/eschf/xvag138 | |
| dc.journal.title | ESC HEART FAILURE |